RNA Interference as a Tool for Alzheimers Disease Therapy

Author(s): Antonio Orlacchio, Giorgio Bernardi, Aldo Orlacchio, Sabata Martino

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 7 , Issue 11 , 2007

Become EABM
Become Reviewer
Call for Editor


RNA interference is a biological process that controls gene silencing in all living cells. Targeting the RNA interference system represents a novel therapeutic strategy able to intercede with multiple disease-related genes and to target many neurodegenerative diseases. Recently, the design of small interfering RNA-selective compounds has become more straightforward because of the significant progress made in predictive modeling for new therapeutic approaches. Although in vivo delivery of RNA interference remains a significant obstacle, new data show that RNAi blocks gene function in vivo, suggesting a potential therapeutic approach for humans. Some groups have demonstrated the efficacy of RNAi therapy in Alzheimers disease. Results, based on animal models, show a down-regulation of the amyloid precursor protein and a consequent reduction of the amyloid-β peptide accumulation in the brain or the inactivation of β-secretase (BACE1). Indeed, lentiviral vectors expressing siRNAs targeting BACE1 reduce amyloid production and the neurodegenerative and behavioural deficit in APP transgenic mice. This review highlights recent advances in RNA research and focuses on strengths and weaknesses of RNAi compounds in Alzheimers disease.

Keywords: amyloid plaque, APP cellular processing, glycogen synthase kinase 3, Neprilysin, Tau phosphorylation

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [1166 - 1176]
Pages: 11
DOI: 10.2174/138955707782331678
Price: $65

Article Metrics

PDF: 7